ClinicalTrials.gg
CompletedNCT04562766LUNA 3Updated Oct 7, 2026Results posted

Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)

A Phase 3 interventional study of Rilzabrutinib and Placebo in Immune Thrombocytopenia, sponsored by Principia Biopharma, a Sanofi Company. Completed at 155 sites in 26 countries. Open to participants aged 10 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Principia Biopharma, a Sanofi Company (part of Sanofi) · Phase 3, Interventional, and Treatment

Updated Oct 7, 2026Now CompletedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
232
Allocation
Randomized
Ages
10 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 110 studies in Purpura, Thrombocytopenic, Idiopathic with a site in United States — 18 open to participants now, 22 under way, 9 of them phase 3. Purpura, Thrombocytopenic, Idiopathic · United States.

Enrollment
2nd of 94
232 · median 42
Started
2020
with 7 others
Phase 3
32 of 110
6 open now
Registered
75th of 110
by date

Among the 110 studies in Purpura, Thrombocytopenic, Idiopathic with a site in United States, this one is the 2nd largest by enrollment of the 94 interventional ones that give a count, is one of 8 that started in 2020, is one of 32 in phase 3, and was the 75th registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

18 of the 110 studies in Purpura, Thrombocytopenic, Idiopathic with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 10 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies in Purpura, Thrombocytopenic, Idiopathic with a site in United States, or all of them as a file.
02

Study summary

This was a randomized, double-blind study of rilzabrutinib in patients with persistent or chronic ITP, with an average platelet count of \<30,000/μL (and no single platelet count >35,000/μL) on two counts at least 5 days apart in the 14 days before treatment begins. Patients received rilzabrutinib or placebo 400mg twice daily.

For each patient, the study lasted up to 60 weeks from the start of the Screening Period to the End of Study (EOS) visit. This included Screening (up to 4 weeks) through a 12 to 24-week Blinded Treatment Period followed by a 28-week Open-Label Period. Followed by a 4-week post dose follow-up.

For adult participants, the maximum duration of the long-term extension (LTE) period was 12 months from the date of the last adult participant to enter the LTE.

For pediatric participants, the maximum duration of the LTE period was 12 months from the date of the last pediatric participant to enter the LTE.

03

Conditions studied

  • Immune Thrombocytopenia
04

Who can participate

Ages eligible
10 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female with primary ITP with duration of >6 months in pediatric participants aged 12 to \<18 years (pediatric participants aged 10 to \<12 years will be enrolled in the EU [EEA countries] only) and duration of >3 months in ages 18 years and above
  2. Patients who had a response (achievement of count ≥50,000/µL) to IVIg/anti-D or CSs that was not sustained and who have documented intolerance, insufficient response or any to any appropriate courses of standard of care ITP therapy
  3. An average of 2 platelet counts at least 5 days apart of \<30,000/µL during the Screening period and no single platelet count >35,000/µL, within 14 days prior to the first dose of study drug.

    - Pediatric patients must additionally be determined to need treatment for ITP as per clinical assessment by the Investigator.

  4. Adequate hematologic, hepatic, and renal function ( ≥1.5 X 10\^9/L, /ALT ≤1.5 x [ULN], albumin ≥3 g/dL, total ≤1.5 x ULN [unless the patient has documented Gilbert syndrome], >50 [Cockcroft and Gault method for adult and Bedside Schwartz Equation for Pediatric participants])
  5. >9 g/dL within 1 week prior to Study Day 1
  6. All use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
  7. Patients must be able to provide written or informed assent with corresponding informed consent obtained from the patient's guardian and agree to the schedule of assessments

Exclusion criteria

Exclusion Criteria:

  1. Patients with secondary ITP
  2. Pregnant or lactating women
  3. History (within 5 years of Study Day 1) or current, active requiring or likely to require chemotherapeutic or surgical treatment during the study, with the exception of non melanoma skin cancer
  4. Transfusion with blood, blood products, plasmapheresis, or use of any other rescue medications with intent to increase count within 14 days before Study Day 1
  5. Change in CS and/or TPO-RA dose within 14 days prior to Study Day 1 (more than 10% variation from current doses)
  6. drugs other than CSs within 5 times the elimination half-life of the drug or 14 days of Study Day 1, whichever is longer
  7. Treatment with rituximab or splenectomy within the 3 months prior to Study Day 1

    - Patients treated with rituximab will have normal B-cell counts prior to enrollment

  8. Had received any drug within the 30 days before receiving the first dose of study medication, or at least 5 times elimination half-life of the drug (whichever is longer); patient should not be using an investigational device at the time of dosing

    • Patients who previously received treatment with Bruton's Tyrosine Kinase (BTK) inhibitors (except rilzabrutinib) within 30 days before the first dose of study drug are not eligible
    • Patients who previously received rilzabrutinib at any time are not eligible
  9. History of solid organ transplant
  10. Myelodysplastic syndrome
  11. within 28 days prior to Study Day 1 or plan to receive one during the study
  12. Planned surgery in the time frame of the dosing period
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
232 participants (actual)

Study arms

  • Experimental
    Rilzabrutinib

    Patients receive rilzabrutinib 400mg orally twice daily for up to 24 weeks followed by 28 weeks of open label period

    Drug: Rilzabrutinib

  • Placebo comparator
    Placebo

    Patients receive matching placebo 400mg orally twice daily for up to 24 weeks

    Drug: Placebo

Interventions

  • 400mg Caplet

    Also known as: PRN1008

  • DrugPlacebo

    400mg Caplet

    Also known as: PRN1008 Placebo

06

What researchers measure

Primary outcomes

  1. DB Period: Percentage of Participants With Durable Platelet Response Per Guidance in Regions Except European Union and United Kingdom

    Durable platelet response per guidance in regions except European Union and United Kingdom was defined as platelet counts at or above 50,000/mcL for \>=two-thirds of at least 8 non-missing weekly scheduled platelet measurements during the last 12 weeks of the 24-week blinded treatment period in the absence of rescue therapy, provided that at least 2 non-missing weekly scheduled platelet measurements were at or above 50,000/mcL during the last 6 weeks of the 24-week blinded treatment period.

    Time frame: Up to 24 weeks

  2. DB Period: Percentage of Participants With Durable Platelet Response Per Guidance in European Union and United Kingdom

    Durable platelet response per guidance in European Union and United Kingdom was defined as platelet counts at or above 50,000/mcL for at least 8 out of the last 12 weeks of the 24-week blinded treatment period in the absence of rescue therapy.

    Time frame: Up to 24 weeks

Secondary outcomes

  1. DB Period: Number of Weeks With Platelet Count >=50,000/mcL or Between >=30,000/mcL and <50,000/mcL and at Least Doubled From Baseline in the Absence of Rescue Therapy

    Number of weeks with platelet response was assessed using clinically meaningful threshold of platelet count \>=50,000/mcL or between \>=30,000/mcL and \<50,000/mcL and at least doubled from baseline over the 24-week blinded treatment period in the absence of rescue therapy.

    Time frame: Up to 24 weeks

  2. DB Period: Number of Weeks With Platelet Counts >=30,000/mcL and at Least Doubled From Baseline in the Absence of Rescue Therapy

    Number of weeks with platelet response was assessed using clinically meaningful threshold of platelet counts \>=30,000/mcL and at least doubled from baseline over the 24-week blinded treatment period in the absence of rescue therapy.

    Time frame: Up to 24 weeks

  3. DB Period: Time to First Platelet Count of >=50,000/mcL or Between >=30,000/mcL and <50,000/mcL and Doubled From Baseline

    Time to first platelet count of \>=50,000/mcL or between \>=30,000/mcL and \<50,000/mcL and doubled from baseline was calculated as: (date of first occurrence of platelet response - date of first study drug intake) + 1.

    Time frame: Up to 24 weeks

  4. DB Period: Percentage of Participants Who Required Rescue Therapy

    Resue therapy included intravenous immunoglobulin (Ig) or high-dose corticosteroids, platelet infusion, or anti-D Ig infusion. Percentage of participants who required rescue therapy are presented.

    Time frame: Up to 24 weeks

  5. DB Period: Change From Baseline on Item 10 (Physical Fatigue) of the Immune Thrombocytopenia-Patient Assessment Questionnaire (ITP-PAQ) in Adult Participants at Week 13

    ITP-PAQ:38 items and 44 items completed by male and female respondents respectively.It included 10 scales:symptoms(6 items:1-6),fatigue/sleep(4 items:7-10),bother-physical health(3 items:11-13),activity(2 items:14-15),psychological health(5 items:16-20),fear(5 items:21-25),overall quality of life(QoL)(5 items:26-30),social activity(4 items:31-34),women's reproductive health(6 items:35-40),work(4 items:41-44).Responses were recorded on 4-point(1:"strongly disagree" to 4:"strongly agree"),5-point(1:"never/not at all" to 5:"all the time/extremely") or 7-point(1:"not at all" to 7:"extremely") Likert scales.Each item score:100x(\[possible maximal item score - item score\]/range).All item scores:transformed to 0 to 100 continuum and were weighted equally to derive scale scores.Total score:0(worst) to 100(best);higher scores:better QoL.Change of positive value:improvement.Change from baseline in physical fatigue is presented.Baseline:last available value before first dose of DB study drug.

    Time frame: Baseline (Day 1) and Week 13

  6. DB Period: Change From Baseline in Idiopathic Thrombocytopenic Purpura Bleeding Scale (IBLS) Assessment in Adult Participants at Week 25 Per Guidance in European Union and United Kingdom

    Per guidance in European Union and United Kingdom, ITP IBLS was a bleeding assessment system which comprised of 11 (10 for male) site-specific grades assessed at 9 anatomical sites by history (Hx) over previous period. In addition, 2 of these sites, skin and oral, were also assessed by physical examination (PE). These 11 grades included: skin (PE), skin (Hx), oral (PE), oral (Hx), epistaxis, gastrointestinal, urinary, gynecological, pulmonary, intracranial hemorrhage, and subconjunctival hemorrhage; scores ranged from 0 (none) to 2 (marked bleeding). For each participant, an IBLS score at each visit was calculated by taking average across 11 items (10 for male and postmenopausal female) at 9 sites (8 for male and postmenopausal female). Total score was calculated as mean value for all 11 grades ranging from 0 (best) to 22 (worst); higher scores indicated worse outcomes. Change of negative value indicates an improvement.Baseline:last available value before first dose of DB study drug.

    Time frame: Baseline (Day 1) and Week 25

  7. DB Period: Change From Baseline in Idiopathic Thrombocytopenic Purpura Bleeding Scale Assessment in Adolescent Participants at Week 25 Per Guidance in European Union and United Kingdom

    Per guidance in European Union and United Kingdom, ITP IBLS was a bleeding assessment system which comprised of 11 (10 for male) site-specific grades assessed at 9 anatomical sites by Hx over previous period. In addition, 2 of these sites, skin and oral, were also assessed by PE. These 11 grades included: skin (PE), skin (Hx), oral (PE), oral (Hx), epistaxis, gastrointestinal, urinary, gynecological, pulmonary, intracranial hemorrhage, and subconjunctival hemorrhage; scores ranged from 0 (none) to 2 (marked bleeding). For each participant, an IBLS score at each visit was calculated by taking average across 11 items (10 for male) at 9 sites (8 for male). Total score was calculated as mean value for all 11 grades ranging from 0 (best) to 22 (worst); higher scores indicated worse outcomes. Change of negative value indicates an improvement. Baseline:last available value before first dose of DB study drug.

    Time frame: Baseline (Day 1) and Week 25

  8. DB-OL Period: Percentage of Participants With Stability of Response in Adult Participants

    Stability of response was defined as the percentage of participants who were able to achieve stable platelet response defined as no 2 scheduled visits, at least 4 weeks apart, with a platelet count \<50,000/mcL, without an intervening visit with a platelet count \>=50,000/mcL, within a period of 24 weeks following initial achievement of the platelet response (initial platelet response defined as platelet count \>=50,000/mcL within 12 weeks of initiation of treatment with rilzabrutinib during the study). This endpoint was assessed from start of DB period through OL period.

    Time frame: Up to 52 weeks

  9. DB-OL Period: Percentage of Participants With Stability of Response in Adolescent Participants

    Time frame: Up to 52 weeks

  10. DB Period: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs) and Bleeding Treatment-Emergent Adverse Events >=Grade 2

    An AE was any untoward medical occurrence in a participant or clinical investigation participant, administered a study drug and which did not necessarily had a causal relationship with the study drug. An SAE was any AE that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was an important medical event. TEAEs were defined as AEs that developed, worsened or became serious during the TE period. Bleeding TEAEs Grade \>=2 (criteria mentioned in statistical analysis plan) are also presented.

    Time frame: From first dose of study drug (Day 1) up to maximum DB exposure, up to 182 days (adults) and up to 175 days (adolescent)

  11. DB Period: Plasma Concentrations of Rilzabrutinib

    Blood samples were collected at specified timepoints for the analysis of plasma concentration of rilzabrutinib.

    Time frame: Pre-dose at Weeks 1, 13 and 25 and 2 hours post-dose at Week 1 and 25 (adults); Pre-dose at Weeks 1, 13 and 25, 0.5, 2, 4 and 6 hours post-dose at Weeks 1 and 25 (adolescent)

  12. DB Period: Change From Baseline in the Symptoms, Bother and Activity Domains of the Immune Thrombocytopenia-Patient Assessment Questionnaire in Adult Participants

    ITP-PAQ:38 items and 44 items completed by male and female respondents respectively.It included 10 scales:symptoms(6 items:1-6),fatigue/sleep(4 items:7-10),bother-physical health(3 items:11-13),activity(2 items:14-15),psychological health(5 items:16-20),fear(5 items:21-25),overall QoL(5 items:26-30),social activity(4 items:31-34),women's reproductive health(6 items:35-40),work(4 items:41-44).Responses were recorded on 4-point(1:"strongly disagree" to 4:"strongly agree"),5-point(1:"never/not at all" to 5:"all the time/extremely") or 7-point(1:"not at all" to 7:"extremely") Likert scales.Each item score:100x(\[possible maximal item score - item score\]/range).All item scores:transformed to 0 to 100 continuum and were weighted equally to derive scale scores.Total score:0(worst) to 100(best);higher scores:better QoL.Change of positive value:improvement.Change from baseline in symptoms,bother and activity domains is presented.Baseline:last available value before first dose of DB study drug.

    Time frame: Baseline (Day 1) and Week 25

  13. DB Period: Change From Baseline in Disease-Specific Quality Of Life as Measured by the Kids' Immune Thrombocytopenia Tools (ITP-KIT) Score in Adolescent Participants

    ITP-KIT was a disease-specific instrument and child self-report form designed to be completed by children \>=7 years. It comprised of total of 27 items among which 26 items were structured as Likert scales with 5 response options 1: "never", 2: "rarely", 3: "sometimes", 4: "often" and 5: "always". An additional "not applicable" option was available for items 18 to 26, which was scored as 1: the same as "never". Item 27 was a descriptive question answered "yes" or "no" which was not included in the calculation of the summary score. Instrument yielded a summary KIT score which was the summation of the items calculated as: 100 x (1- \[{sum of all valid responses - number of valid responses}/{number of valid responses\*4}\]). Scores were converted to a 0 to 100 with higher scores indicating better disease-specific QoL. Change from baseline of positive value indicated improvement. Baseline was defined as the last available value before first dose of DB study drug.

    Time frame: Baseline (Day 1) and Week 25

07

Results

Posted Feb 23, 2026

Participant flow

The study was conducted at 92 centers in 25 countries for adult participants and 20 centers in 11 countries for adolescent participants. 393 adult and 51 adolescent participants were screened between 14 December 2020 to 30 September 2024, of which 191 adult and 21 adolescent participants were screen failures. Screen failures were mainly due to not meeting eligibility criteria.

DB Period (Weeks 1 to 24)
Participant flow — DB Period (Weeks 1 to 24)
MilestoneDB Period: Adults: PlaceboDB Period: Adults: Rilzabrutinib 400 mg BIDDB Period: Adolescent: PlaceboDB Period: Adolescent: Rilzabrutinib 400 mg BIDOL Period: Adults: Rilzabrutinib 400 mg BIDOL Period: Adolescent: Rilzabrutinib 400 mg BIDLTE Period: Adults: Rilzabrutinib 400 mg BIDLTE Period: Adolescent: Rilzabrutinib 400 mg BID
Started6913312180000
Completed 12-week db period6612112180000
Completed1062270000
Not completed597110110000
Withdrew: Withdrawal by subject27000000
Withdrew: Adverse event08000000
Withdrew: Participant was non-compliant to study requirements10000000
Withdrew: Lack of response555510110000
Withdrew: Sponsor discretion10000000
Withdrew: Other01000000
OL Period (From Week 25 to Week 53)
Participant flow — OL Period (From Week 25 to Week 53)
MilestoneDB Period: Adults: PlaceboDB Period: Adults: Rilzabrutinib 400 mg BIDDB Period: Adolescent: PlaceboDB Period: Adolescent: Rilzabrutinib 400 mg BIDOL Period: Adults: Rilzabrutinib 400 mg BIDOL Period: Adolescent: Rilzabrutinib 400 mg BIDLTE Period: Adults: Rilzabrutinib 400 mg BIDLTE Period: Adolescent: Rilzabrutinib 400 mg BID
Started00001803000
Completed00001151000
Not completed0000652000
Withdrew: Withdrawal by subject000021400
Withdrew: Adverse event00006000
Withdrew: Lost to follow-up00001000
Withdrew: Lack of response000033600
Withdrew: Other00004000
Withdrew: Ongoing000001000
LTE(Weeks 53-183[Adult]&147[Adolescent])
Participant flow — LTE(Weeks 53-183[Adult]&147[Adolescent])
MilestoneDB Period: Adults: PlaceboDB Period: Adults: Rilzabrutinib 400 mg BIDDB Period: Adolescent: PlaceboDB Period: Adolescent: Rilzabrutinib 400 mg BIDOL Period: Adults: Rilzabrutinib 400 mg BIDOL Period: Adolescent: Rilzabrutinib 400 mg BIDLTE Period: Adults: Rilzabrutinib 400 mg BIDLTE Period: Adolescent: Rilzabrutinib 400 mg BID
Started000000694
Completed00000010
Not completed000000684
Withdrew: Withdrawal by subject00000021
Withdrew: Pregnancy00000010
Withdrew: Lack of response00000011
Withdrew: Other00000010
Withdrew: Sponsor discretion00000010
Withdrew: Adverse event00000010
Withdrew: Ongoing000000612

Outcome measures

PrimaryDB Period: Percentage of Participants With Durable Platelet Response Per Guidance in Regions Except European Union and United Kingdom

Durable platelet response per guidance in regions except European Union and United Kingdom was defined as platelet counts at or above 50,000/mcL for \>=two-thirds of at least 8 non-missing weekly scheduled platelet measurements during the last 12 weeks of the 24-week blinded treatment period in the absence of rescue therapy, provided that at least 2 non-missing weekly scheduled platelet measurements were at or above 50,000/mcL during the last 6 weeks of the 24-week blinded treatment period.

Time frame:
Up to 24 weeks
Reported as:
Number · percentage of participants
DB Period: Percentage of Participants With Durable Platelet Response Per Guidance in Regions Except European Union and United Kingdom
percentage of participantsDB Period: Adults: PlaceboDB Period: Adults: Rilzabrutinib 400 mg BIDDB Period: Adolescent: PlaceboDB Period: Adolescent: Rilzabrutinib 400 mg BID
DB Period: Percentage of Participants With Durable Platelet Response Per Guidance in Regions Except European Union and United Kingdom0.0 (0.00 to 0.00)23.3 (16.12 to 30.49)0.0 (0.00 to 26.46)11.1 (1.38 to 34.71)
Statistical analysis
  • DB Period: Adults: Placebo vs DB Period: Adults: Rilzabrutinib 400 mg BID · Cochran-Mantel-Haenszel · p = <0.0001 · Risk difference (rd): 23.1 · 95% CI 15.95 to 30.31Mantel-Haenszel estimate based on Mantel-Haenszel stratum weights and the Sato variance estimator.
PrimaryDB Period: Percentage of Participants With Durable Platelet Response Per Guidance in European Union and United Kingdom

Durable platelet response per guidance in European Union and United Kingdom was defined as platelet counts at or above 50,000/mcL for at least 8 out of the last 12 weeks of the 24-week blinded treatment period in the absence of rescue therapy.

Time frame:
Up to 24 weeks
Reported as:
Number · percentage of participants
DB Period: Percentage of Participants With Durable Platelet Response Per Guidance in European Union and United Kingdom
percentage of participantsDB Period: Adults: PlaceboDB Period: Adults: Rilzabrutinib 400 mg BIDDB Period: Adolescent: PlaceboDB Period: Adolescent: Rilzabrutinib 400 mg BID
DB Period: Percentage of Participants With Durable Platelet Response Per Guidance in European Union and United Kingdom0.0 (0.00 to 0.00)23.3 (16.12 to 30.49)0.0 (0.00 to 26.46)11.1 (1.38 to 34.71)
Statistical analysis
  • DB Period: Adults: Placebo vs DB Period: Adults: Rilzabrutinib 400 mg BID · Cochran-Mantel-Haenszel · p = <0.0001 · Risk difference (rd): 23.1 · 95% CI 15.95 to 30.31Mantel-Haenszel estimate based on Mantel-Haenszel stratum weights and the Sato variance estimator.
SecondaryDB Period: Number of Weeks With Platelet Count >=50,000/mcL or Between >=30,000/mcL and <50,000/mcL and at Least Doubled From Baseline in the Absence of Rescue Therapy

Number of weeks with platelet response was assessed using clinically meaningful threshold of platelet count \>=50,000/mcL or between \>=30,000/mcL and \<50,000/mcL and at least doubled from baseline over the 24-week blinded treatment period in the absence of rescue therapy.

Time frame:
Up to 24 weeks
Reported as:
Mean · weeks
DB Period: Number of Weeks With Platelet Count >=50,000/mcL or Between >=30,000/mcL and <50,000/mcL and at Least Doubled From Baseline in the Absence of Rescue Therapy
weeksDB Period: Adults: PlaceboDB Period: Adults: Rilzabrutinib 400 mg BIDDB Period: Adolescent: PlaceboDB Period: Adolescent: Rilzabrutinib 400 mg BID
DB Period: Number of Weeks With Platelet Count >=50,000/mcL or Between >=30,000/mcL and <50,000/mcL and at Least Doubled From Baseline in the Absence of Rescue Therapy1.0 ± 2.147.5 ± 8.740.8 ± 1.544.2 ± 7.73
Statistical analysis
  • DB Period: Adults: Placebo vs DB Period: Adults: Rilzabrutinib 400 mg BID · Mixed-effect model with repeated measure · p = <0.0001 · Least squares (ls) mean difference: 6.46 · 95% CI 4.923 to 7.990Mixed-effect model with repeated measures (MMRM) on longitudinal binary data with treatment, stratification factors, week (Weeks 2 to 25), treatment-by-week interaction as categorical fix effects.
SecondaryDB Period: Number of Weeks With Platelet Counts >=30,000/mcL and at Least Doubled From Baseline in the Absence of Rescue Therapy

Number of weeks with platelet response was assessed using clinically meaningful threshold of platelet counts \>=30,000/mcL and at least doubled from baseline over the 24-week blinded treatment period in the absence of rescue therapy.

Time frame:
Up to 24 weeks
Reported as:
Mean · weeks
DB Period: Number of Weeks With Platelet Counts >=30,000/mcL and at Least Doubled From Baseline in the Absence of Rescue Therapy
weeksDB Period: Adults: PlaceboDB Period: Adults: Rilzabrutinib 400 mg BIDDB Period: Adolescent: PlaceboDB Period: Adolescent: Rilzabrutinib 400 mg BID
DB Period: Number of Weeks With Platelet Counts >=30,000/mcL and at Least Doubled From Baseline in the Absence of Rescue Therapy1.0 ± 2.017.3 ± 8.700.6 ± 1.084.1 ± 7.76
Statistical analysis
  • DB Period: Adults: Placebo vs DB Period: Adults: Rilzabrutinib 400 mg BID · MMRM · p = <0.0001 · Ls mean difference: 6.31 · 95% CI 4.787 to 7.831MMRM on longitudinal binary data with treatment, stratification factors, week (Weeks 2 to 25), treatment-by- week interaction as categorical fix effects.
SecondaryDB Period: Time to First Platelet Count of >=50,000/mcL or Between >=30,000/mcL and <50,000/mcL and Doubled From Baseline

Time to first platelet count of \>=50,000/mcL or between \>=30,000/mcL and \<50,000/mcL and doubled from baseline was calculated as: (date of first occurrence of platelet response - date of first study drug intake) + 1.

Time frame:
Up to 24 weeks
Reported as:
Median · days
DB Period: Time to First Platelet Count of >=50,000/mcL or Between >=30,000/mcL and <50,000/mcL and Doubled From Baseline
daysDB Period: Adults: PlaceboDB Period: Adults: Rilzabrutinib 400 mg BIDDB Period: Adolescent: PlaceboDB Period: Adolescent: Rilzabrutinib 400 mg BID
DB Period: Time to First Platelet Count of >=50,000/mcL or Between >=30,000/mcL and <50,000/mcL and Doubled From BaselineNA (NA to NA)36.0 (22.00 to 44.00)NA (62.00 to NA)74.5 (9.00 to NA)
Statistical analysis
  • DB Period: Adults: Placebo vs DB Period: Adults: Rilzabrutinib 400 mg BID · Log Rank · p = <0.0001 · Hazard ratio (hr): 3.10 · 95% CI 1.948 to 4.934Cox regression model with treatment group and stratification factors as covariates.
SecondaryDB Period: Percentage of Participants Who Required Rescue Therapy

Resue therapy included intravenous immunoglobulin (Ig) or high-dose corticosteroids, platelet infusion, or anti-D Ig infusion. Percentage of participants who required rescue therapy are presented.

Time frame:
Up to 24 weeks
Reported as:
Number · percentage of participants
DB Period: Percentage of Participants Who Required Rescue Therapy
percentage of participantsDB Period: Adults: PlaceboDB Period: Adults: Rilzabrutinib 400 mg BIDDB Period: Adolescent: PlaceboDB Period: Adolescent: Rilzabrutinib 400 mg BID
DB Period: Percentage of Participants Who Required Rescue Therapy58.033.141.727.8
Statistical analysis
  • DB Period: Adults: Placebo vs DB Period: Adults: Rilzabrutinib 400 mg BID · Cochran-Mantel-Haenszel · p = 0.0007 · Risk difference (rd): -24.7 · 95% CI -38.73 to -10.71Mantel-Haenszel estimate based on Mantel-Haenszel stratum weights and the Sato variance estimator.
SecondaryDB Period: Change From Baseline on Item 10 (Physical Fatigue) of the Immune Thrombocytopenia-Patient Assessment Questionnaire (ITP-PAQ) in Adult Participants at Week 13

ITP-PAQ:38 items and 44 items completed by male and female respondents respectively.It included 10 scales:symptoms(6 items:1-6),fatigue/sleep(4 items:7-10),bother-physical health(3 items:11-13),activity(2 items:14-15),psychological health(5 items:16-20),fear(5 items:21-25),overall quality of life(QoL)(5 items:26-30),social activity(4 items:31-34),women's reproductive health(6 items:35-40),work(4 items:41-44).Responses were recorded on 4-point(1:"strongly disagree" to 4:"strongly agree"),5-point(1:"never/not at all" to 5:"all the time/extremely") or 7-point(1:"not at all" to 7:"extremely") Likert scales.Each item score:100x(\[possible maximal item score - item score\]/range).All item scores:transformed to 0 to 100 continuum and were weighted equally to derive scale scores.Total score:0(worst) to 100(best);higher scores:better QoL.Change of positive value:improvement.Change from baseline in physical fatigue is presented.Baseline:last available value before first dose of DB study drug.

Time frame:
Baseline (Day 1) and Week 13
Reported as:
Least squares mean · score on a scale
DB Period: Change From Baseline on Item 10 (Physical Fatigue) of the Immune Thrombocytopenia-Patient Assessment Questionnaire (ITP-PAQ) in Adult Participants at Week 13
score on a scaleDB Period: Adults: PlaceboDB Period: Adults: Rilzabrutinib 400 mg BID
DB Period: Change From Baseline on Item 10 (Physical Fatigue) of the Immune Thrombocytopenia-Patient Assessment Questionnaire (ITP-PAQ) in Adult Participants at Week 13-0.13 ± 2.8617.95 ± 2.132
Statistical analysis
  • DB Period: Adults: Placebo vs DB Period: Adults: Rilzabrutinib 400 mg BID · ANCOVA · p = 0.0114 · Ls mean difference: 8.08 · 95% CI 1.818 to 14.337Analysis of covariance (ANCOVA) model with the treatment group and stratification factors as fixed effects and baseline item 10 score as a covariate.
SecondaryDB Period: Change From Baseline in Idiopathic Thrombocytopenic Purpura Bleeding Scale (IBLS) Assessment in Adult Participants at Week 25 Per Guidance in European Union and United Kingdom

Per guidance in European Union and United Kingdom, ITP IBLS was a bleeding assessment system which comprised of 11 (10 for male) site-specific grades assessed at 9 anatomical sites by history (Hx) over previous period. In addition, 2 of these sites, skin and oral, were also assessed by physical examination (PE). These 11 grades included: skin (PE), skin (Hx), oral (PE), oral (Hx), epistaxis, gastrointestinal, urinary, gynecological, pulmonary, intracranial hemorrhage, and subconjunctival hemorrhage; scores ranged from 0 (none) to 2 (marked bleeding). For each participant, an IBLS score at each visit was calculated by taking average across 11 items (10 for male and postmenopausal female) at 9 sites (8 for male and postmenopausal female). Total score was calculated as mean value for all 11 grades ranging from 0 (best) to 22 (worst); higher scores indicated worse outcomes. Change of negative value indicates an improvement.Baseline:last available value before first dose of DB study drug.

Time frame:
Baseline (Day 1) and Week 25
Reported as:
Least squares mean · score on a scale
DB Period: Change From Baseline in Idiopathic Thrombocytopenic Purpura Bleeding Scale (IBLS) Assessment in Adult Participants at Week 25 Per Guidance in European Union and United Kingdom
score on a scaleDB Period: Adults: PlaceboDB Period: Adults: Rilzabrutinib 400 mg BID
DB Period: Change From Baseline in Idiopathic Thrombocytopenic Purpura Bleeding Scale (IBLS) Assessment in Adult Participants at Week 25 Per Guidance in European Union and United Kingdom0.047 ± 0.0226-0.040 ± 0.0169
Statistical analysis
  • DB Period: Adults: Placebo vs DB Period: Adults: Rilzabrutinib 400 mg BID · ANCOVA · p = 0.0006 · Ls mean difference: -0.087 · 95% CI -0.1358 to -0.0373ANCOVA model with the treatment group and stratification factors as fixed effects and baseline score as a covariate.
SecondaryDB Period: Change From Baseline in Idiopathic Thrombocytopenic Purpura Bleeding Scale Assessment in Adolescent Participants at Week 25 Per Guidance in European Union and United Kingdom

Per guidance in European Union and United Kingdom, ITP IBLS was a bleeding assessment system which comprised of 11 (10 for male) site-specific grades assessed at 9 anatomical sites by Hx over previous period. In addition, 2 of these sites, skin and oral, were also assessed by PE. These 11 grades included: skin (PE), skin (Hx), oral (PE), oral (Hx), epistaxis, gastrointestinal, urinary, gynecological, pulmonary, intracranial hemorrhage, and subconjunctival hemorrhage; scores ranged from 0 (none) to 2 (marked bleeding). For each participant, an IBLS score at each visit was calculated by taking average across 11 items (10 for male) at 9 sites (8 for male). Total score was calculated as mean value for all 11 grades ranging from 0 (best) to 22 (worst); higher scores indicated worse outcomes. Change of negative value indicates an improvement. Baseline:last available value before first dose of DB study drug.

Time frame:
Baseline (Day 1) and Week 25
Reported as:
Mean · score on a scale
DB Period: Change From Baseline in Idiopathic Thrombocytopenic Purpura Bleeding Scale Assessment in Adolescent Participants at Week 25 Per Guidance in European Union and United Kingdom
score on a scaleDB Period: Adolescent: PlaceboDB Period: Adolescent: Rilzabrutinib 400 mg BID
DB Period: Change From Baseline in Idiopathic Thrombocytopenic Purpura Bleeding Scale Assessment in Adolescent Participants at Week 25 Per Guidance in European Union and United Kingdom-0.09 ± 0.13-0.04 ± 0.15
SecondaryDB-OL Period: Percentage of Participants With Stability of Response in Adult Participants

Stability of response was defined as the percentage of participants who were able to achieve stable platelet response defined as no 2 scheduled visits, at least 4 weeks apart, with a platelet count \<50,000/mcL, without an intervening visit with a platelet count \>=50,000/mcL, within a period of 24 weeks following initial achievement of the platelet response (initial platelet response defined as platelet count \>=50,000/mcL within 12 weeks of initiation of treatment with rilzabrutinib during the study). This endpoint was assessed from start of DB period through OL period.

Time frame:
Up to 52 weeks
Reported as:
Number · percentage of participants
DB-OL Period: Percentage of Participants With Stability of Response in Adult Participants
percentage of participantsDB-OL Period: Adults: Placebo in DBDB-OL Period: Adults: Rilzabrutinib 400 mg BID in DBDB-OL Period: Adults: Rilzabrutinib 400 mg BID
DB-OL Period: Percentage of Participants With Stability of Response in Adult Participants23.1 (12.83 to 33.32)23.3 (16.12 to 30.49)23.2 (17.35 to 29.11)
SecondaryDB-OL Period: Percentage of Participants With Stability of Response in Adolescent Participants
Time frame:
Up to 52 weeks

Results for this outcome have not been posted.

SecondaryDB Period: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs) and Bleeding Treatment-Emergent Adverse Events >=Grade 2

An AE was any untoward medical occurrence in a participant or clinical investigation participant, administered a study drug and which did not necessarily had a causal relationship with the study drug. An SAE was any AE that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was an important medical event. TEAEs were defined as AEs that developed, worsened or became serious during the TE period. Bleeding TEAEs Grade \>=2 (criteria mentioned in statistical analysis plan) are also presented.

Time frame:
From first dose of study drug (Day 1) up to maximum DB exposure, up to 182 days (adults) and up to 175 days (adolescent)
Reported as:
Count of participants · Participants
DB Period: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs) and Bleeding Treatment-Emergent Adverse Events >=Grade 2
ParticipantsDB Period: Adults: PlaceboDB Period: Adults: Rilzabrutinib 400 mg BIDDB Period: Adolescent: PlaceboDB Period: Adolescent: Rilzabrutinib 400 mg BID
Any TEAE521111015
Any TESAE81202
Any Bleeding TEAEs >=Grade 28502
SecondaryDB Period: Plasma Concentrations of Rilzabrutinib

Blood samples were collected at specified timepoints for the analysis of plasma concentration of rilzabrutinib.

Time frame:
Pre-dose at Weeks 1, 13 and 25 and 2 hours post-dose at Week 1 and 25 (adults); Pre-dose at Weeks 1, 13 and 25, 0.5, 2, 4 and 6 hours post-dose at Weeks 1 and 25 (adolescent)
Reported as:
Mean · nanogram per milliliter (ng/mL)
DB Period: Plasma Concentrations of Rilzabrutinib
nanogram per milliliter (ng/mL)DB Period: Adults: Rilzabrutinib 400 mg BIDDB Period: Adolescent: Rilzabrutinib 400 mg BID
Week 1: Pre-dose3.15 ± 24.060.00 ± 0.00
Week 1: 0.5 hour post-dose—34.51 ± 40.24
Week 1: 2 hours post-dose178.95 ± 163.47101.45 ± 74.07
Week 1: 4 hours post-dose—52.62 ± 33.70
Week 1: 6 hours post-dose—21.99 ± 22.49
Week 13: Pre-dose27.05 ± 71.265.56 ± 6.88
Week 25: Pre-dose26.31 ± 59.488.57 ± 20.47
Week 25: 0.5 hour post-dose—81.27 ± 70.06
Week 25: 2 hours post-dose254.10 ± 237.11163.21 ± 155.18
Week 25: 4 hours post-dose—72.23 ± 66.37
Week 25: 6 hours post-dose—21.54 ± 11.81
SecondaryDB Period: Change From Baseline in the Symptoms, Bother and Activity Domains of the Immune Thrombocytopenia-Patient Assessment Questionnaire in Adult Participants

ITP-PAQ:38 items and 44 items completed by male and female respondents respectively.It included 10 scales:symptoms(6 items:1-6),fatigue/sleep(4 items:7-10),bother-physical health(3 items:11-13),activity(2 items:14-15),psychological health(5 items:16-20),fear(5 items:21-25),overall QoL(5 items:26-30),social activity(4 items:31-34),women's reproductive health(6 items:35-40),work(4 items:41-44).Responses were recorded on 4-point(1:"strongly disagree" to 4:"strongly agree"),5-point(1:"never/not at all" to 5:"all the time/extremely") or 7-point(1:"not at all" to 7:"extremely") Likert scales.Each item score:100x(\[possible maximal item score - item score\]/range).All item scores:transformed to 0 to 100 continuum and were weighted equally to derive scale scores.Total score:0(worst) to 100(best);higher scores:better QoL.Change of positive value:improvement.Change from baseline in symptoms,bother and activity domains is presented.Baseline:last available value before first dose of DB study drug.

Time frame:
Baseline (Day 1) and Week 25
Reported as:
Mean · score on a scale
DB Period: Change From Baseline in the Symptoms, Bother and Activity Domains of the Immune Thrombocytopenia-Patient Assessment Questionnaire in Adult Participants
score on a scaleDB Period: Adults: PlaceboDB Period: Adults: Rilzabrutinib 400 mg BID
Symptoms2.08 ± 12.9210.28 ± 17.28
Bother-physical health-4.72 ± 19.699.98 ± 20.14
Activity-1.25 ± 25.999.96 ± 19.94
SecondaryDB Period: Change From Baseline in Disease-Specific Quality Of Life as Measured by the Kids' Immune Thrombocytopenia Tools (ITP-KIT) Score in Adolescent Participants

ITP-KIT was a disease-specific instrument and child self-report form designed to be completed by children \>=7 years. It comprised of total of 27 items among which 26 items were structured as Likert scales with 5 response options 1: "never", 2: "rarely", 3: "sometimes", 4: "often" and 5: "always". An additional "not applicable" option was available for items 18 to 26, which was scored as 1: the same as "never". Item 27 was a descriptive question answered "yes" or "no" which was not included in the calculation of the summary score. Instrument yielded a summary KIT score which was the summation of the items calculated as: 100 x (1- \[{sum of all valid responses - number of valid responses}/{number of valid responses\*4}\]). Scores were converted to a 0 to 100 with higher scores indicating better disease-specific QoL. Change from baseline of positive value indicated improvement. Baseline was defined as the last available value before first dose of DB study drug.

Time frame:
Baseline (Day 1) and Week 25
Reported as:
Mean · score on a scale
DB Period: Change From Baseline in Disease-Specific Quality Of Life as Measured by the Kids' Immune Thrombocytopenia Tools (ITP-KIT) Score in Adolescent Participants
score on a scaleDB Period: Adolescent: PlaceboDB Period: Adolescent: Rilzabrutinib 400 mg BID
DB Period: Change From Baseline in Disease-Specific Quality Of Life as Measured by the Kids' Immune Thrombocytopenia Tools (ITP-KIT) Score in Adolescent Participants9.6 ± 6.82.0 ± 11.9

Adverse events

Collected over Adverse events and all-cause mortality (deaths) were collected: DB period: From first dose of study drug (Day 1) up to maximum DB exposure, up to 182 days for adults and up to 175 days for adolescent participants; Adult OL period: From first dose of study drug in OL period (Day 1) up to maximum OL exposure, up to 215 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DB Period: Adults: Placebo0/69 (0%)8/69 (11.6%)33/69 (47.8%)
DB Period: Adults: Rilzabrutinib 400 mg BID1/133 (0.8%)12/133 (9%)90/133 (67.7%)
DB Period: Adolescent: Placebo0/12 (0%)0/12 (0%)10/12 (83.3%)
DB Period: Adolescent: Rilzabrutinib 400 mg BID0/18 (0%)2/18 (11.1%)15/18 (83.3%)
OL Period: Adults: Rilzabrutinib 400 mg BID0/180 (0%)17/180 (9.4%)94/180 (52.2%)
Most frequent serious events
Showing 10 of 32
Most frequent serious events
EventDB Period: Adults: PlaceboDB Period: Adults: Rilzabrutinib 400 mg BIDDB Period: Adolescent: PlaceboDB Period: Adolescent: Rilzabrutinib 400 mg BIDOL Period: Adults: Rilzabrutinib 400 mg BID
EpistaxisRespiratory, thoracic and mediastinal disorders0/691/1330/121/181/180
Ovarian Cyst RupturedReproductive system and breast disorders0/690/1330/121/180/180
ThrombocytopeniaBlood and lymphatic system disorders2/691/1330/120/185/180
Immune ThrombocytopeniaBlood and lymphatic system disorders1/691/1330/120/180/180
Conjunctival HaemorrhageEye disorders1/690/1330/120/180/180
HaematemesisGastrointestinal disorders1/690/1330/120/180/180
Mouth HaemorrhageGastrointestinal disorders1/690/1330/120/180/180
PurpuraSkin and subcutaneous tissue disorders1/690/1330/120/180/180
Heavy Menstrual BleedingReproductive system and breast disorders1/690/1330/120/181/180
Covid-19Infections and infestations0/691/1330/120/180/180
Most frequent other events
Showing 10 of 48
Most frequent other events
EventDB Period: Adults: PlaceboDB Period: Adults: Rilzabrutinib 400 mg BIDDB Period: Adolescent: PlaceboDB Period: Adolescent: Rilzabrutinib 400 mg BIDOL Period: Adults: Rilzabrutinib 400 mg BID
NauseaGastrointestinal disorders4/6927/1330/126/1821/180
DiarrhoeaGastrointestinal disorders7/6943/1330/121/1823/180
HeadacheNervous system disorders5/6924/1332/122/1815/180
Upper Respiratory Tract InfectionInfections and infestations3/695/1332/122/1812/180
Iron Deficiency AnaemiaBlood and lymphatic system disorders3/691/1332/121/180/180
CoughRespiratory, thoracic and mediastinal disorders0/696/1332/122/183/180
Oropharyngeal PainRespiratory, thoracic and mediastinal disorders1/693/1332/121/182/180
VomitingGastrointestinal disorders1/699/1330/123/187/180
PyrexiaGeneral disorders0/695/1332/121/185/180
Covid-19Infections and infestations3/6917/1330/121/1812/180

Baseline characteristics

Adult and adolescent randomized population included all participants from screened population who were allocated to a randomized study drug by interactive response technology regardless of whether the study drug was received or not.

Age, Continuous
Age, Continuous(years)DB Period: Adults: PlaceboDB Period: Adults: Rilzabrutinib 400 mg BIDDB Period: Adolescent: PlaceboDB Period: Adolescent: Rilzabrutinib 400 mg BIDTotal
Mean47.1 ± 18.046.8 ± 17.114.2 ± 1.914.6 ± 1.442.7 ± 19.6
Sex: Female, Male
Sex: Female, Male(Participants)DB Period: Adults: PlaceboDB Period: Adults: Rilzabrutinib 400 mg BIDDB Period: Adolescent: PlaceboDB Period: Adolescent: Rilzabrutinib 400 mg BIDTotal
Female497879143
Male20555989
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)DB Period: Adults: PlaceboDB Period: Adults: Rilzabrutinib 400 mg BIDDB Period: Adolescent: PlaceboDB Period: Adolescent: Rilzabrutinib 400 mg BIDTotal
American Indian or Alaska Native13004
Asian24408880
Black or African American01012
White408536134
Unknown or Not Reported21036
Other23106
08

Study locations

155 sites
  • University of Southern California_Investigational Site Number 84024
    Los Angeles, California 90033, United States
  • UCSF Benioff Children's Hospital San Francisco_Investigational Site Number 84020
    San Francisco, California 94158, United States
  • Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center_Investigational Site Number 84037
    Torrance, California 90502, United States
  • The Oncology Institute of Hope and Innovation_Investigational Site Number 84031
    Whittier, California 90602, United States
  • Children's Hospital Colorado_Investigational Site Number 84025
    Aurora, Colorado 80045, United States
  • IMMUNOe International Research Centers_Investigational Site Number 84028
    Centennial, Colorado 80112, United States
  • ASCLEPES Research Centers_Investigational Site Number 84023
    Weeki Wachee, Florida 34607, United States
  • Children's Healthcare of Atlanta_Investigational Site Number 84034
    Atlanta, Georgia 30322, United States
  • Rush University Medical Center_Investigational Site Number 84029
    Chicago, Illinois 60612, United States
  • University of Louisville - James Graham Brown Cancer Center_Investigational Site Number 84033
    Louisville, Kentucky 40202, United States
  • Massachusetts General Hospital Site Number : 84038
    Boston, Massachusetts 02114, United States
  • Montefiore Medical Center_Investigational Site Number 84032
    The Bronx, New York 10461, United States
  • University Hospitals Cleveland Medical Center Site Number : 84036
    Cleveland, Ohio 44106, United States
  • Cleveland Clinic_Investigational Site Number 84026
    Cleveland, Ohio 44195, United States
  • The Children's Hospital of Philadelphia (CHOP)_Investigational Site Number 84027
    Philadelphia, Pennsylvania 19104, United States
  • University of Utah-Huntsman Cancer Institute_Investigational Site Number 84035
    Salt Lake City, Utah 84112, United States
  • University of Washington Medical Centre Site Number : 84041
    Seattle, Washington 98195, United States
  • Investigational Site Number : 3206
    Capital Federal, Buenos Aires C1280AEB, Argentina
  • Investigational Site Number : 3211
    La Plata, Buenos Aires B1900, Argentina
  • Investigational Site Number : 3205
    Córdoba, Córdoba Province X5003DCE, Argentina
  • Investigational Site Number : 3209
    Corrientes, W3410 FND, Argentina
  • Investigational Site Number : 3208
    San Juan, 5400, Argentina
  • Investigational Site Number : 3607
    Kogarah, New South Wales 2217, Australia
  • Investigational Site Number : 3608
    Westmead, New South Wales 2145, Australia
  • Investigational Site Number : 3611
    Brisbane, Queensland 4101, Australia
  • Investigational Site Number : 3609
    Adelaide, South Australia 5000, Australia
  • Investigational Site Number : 3606
    Frankston, Victoria 3199, Australia
  • Investigational Site Number : 3610
    Perth, Western Australia 6000, Australia
  • Investigational Site Number : 4005
    Graz, 8036, Austria
  • Investigational Site Number : 4004
    Leoben, 8700, Austria
  • Investigational Site Number : 4001
    Linz, A4020, Austria
  • Investigational Site Number : 4003
    Steyr, 4400, Austria
  • Investigational Site Number : 4002
    Vienna, 1140, Austria
  • Hospital Sao Rafael Instituto D'Or da Bahia Site Number : 7608
    Salvador, Estado de Bahia 41253190, Brazil
  • Uniao Oeste Paranaense de Estudos e Combates ao Cancer Site Number : 7610
    Cascavel, Paraná 85806-300, Brazil
  • Hospital De Clinicas De Porto Alegre Site Number : 7605
    Porto Alegre, Rio Grande do Sul 90035 003, Brazil
  • Hospital Santa Marcelina Site Number : 7611
    São Paulo, São Paulo 08270-070, Brazil
  • CEMEC Oncologica do Brasil Site Number : 7606
    Belém, 66053-000, Brazil
  • HEMORIO - Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti Site Number : 7609
    Rio de Janeiro, 20211030, Brazil
  • Hospital do Servidor Publico Estadual de Sao Paulo Site Number : 7607
    São Paulo, 04039-004, Brazil
  • Investigational Site Number : 12404
    Edmonton, Alberta T6G 2P4, Canada
  • Investigational Site Number : 12406
    Toronto, Ontario M5G 1X8, Canada
  • CHU Sainte-Justine_Investigational site number 12405
    Montreal, Quebec H3T 1C5, Canada
  • Investigational Site Number : 15201
    La Serena, Coquimbo Region 1720430, Chile
  • Investigational Site Number : 15204
    Santiago, Reg Metropolitana de Santiago 7500653, Chile
  • Investigational Site Number : 15202
    Viña del Mar, Valparaiso 322000, Chile
  • Wuhan Union Hospital of Tongji Medical College of HUST - Investigational Site Number: 15601
    Wuhan, Hubei 430022, China
  • Shengjing Hospital of China Medical University - Investigational Site Number: 15603
    Shenyang, Liaoning 110022, China
  • Shaanxi Provincial People's Hospital - Investigational Site Number: 15607
    Xi'an, Shaanxi 710068, China
  • Qilu Hospital of Shandong University - Investigational Site Number: 15605
    Jinan, Shandong 250012, China
  • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences - Investigational Site Number: 15602
    Tianjin, Tianjin Municipality 300020, China
  • Second Affiliated Hospital of Kunming Medical University - Investigational Site Number: 15604
    Kunming, Yunnan 650101, China
  • Investigational Site Number : 15611
    Hangzhou, 310018, China
  • Investigational Site Number : 15608
    Hefei, China
  • Investigational Site Number : 15610
    Nanchang, 330006, China
  • Investigational Site Number : 15613
    Tangshan, 63000, China
  • Investigational Site Number : 15609
    Wuxi, 214023, China
  • Investigational Site Number : 15614
    Zhenjiang, 212001, China
  • Investigational Site Number : 25014
    Angers, 49933, France
  • Investigational Site Number : 25011
    Créteil, 94000, France
  • Investigational Site Number : 25010
    Dijon, 21079, France
  • Investigational Site Number : 25009
    Nantes, 44093, France
  • Investigational Site Number : 25008
    Paris, 75012, France
  • Investigational Site Number : 25012
    Paris, 75019, France
  • Investigational Site Number : 25007
    Pessac, 33600, France
  • Investigational Site Number : 27610
    Berlin, 10117, Germany
  • Investigational Site Number 27612
    Düsseldorf, 40497, Germany
  • Investigational Site Number : 27613
    Frankfurt am Main, 60596, Germany
  • Investigational Site Number : 27611
    Recklinghausen, 45659, Germany
  • Investigational Site Number : 34803
    Budapest, 1083, Hungary
  • Investigational Site Number : 34805
    Debrecen, 4032, Hungary
  • Investigational Site Number : 34801
    Győr, 9024, Hungary
  • Investigational Site Number : 34804
    Nyíregyháza, 4405, Hungary
  • Investigational Site Number : 34802
    Székesfehérvár, 8000, Hungary
  • Investigational Site Number : 37605
    Haifa, 3109601, Israel
  • Investigational Site Number : 37606
    Kfar Saba, 4428164, Israel
  • Investigational Site Number : 37607
    Tel Aviv, 6423906, Israel
  • Investigational Site Number : 37608
    Tel Litwinsky, 52621, Israel
  • Investigational Site Number : 37609
    Ẕerifin, 70300, Israel
  • Investigational Site Number : 38014
    Florence, Tuscany 50134, Italy
  • Investigational Site Number : 38012
    Bologna, 40138, Italy
  • Investigational Site Number : 38015
    Milan, 20123, Italy
  • Investigational Site Number : 38013
    Milan, 20142, Italy
  • Investigational Site Number : 38010
    Trieste, 34125, Italy
  • Investigational Site Number : 38011
    Vicenza, 36100, Italy
  • Investigational Site Number : 39214
    Tsuchiura-shi, Ibaraki, Japan
  • Investigational Site Number : 39205
    Kanazawa, Ishikawa-ken 920-8530, Japan
  • Investigational Site Number : 39207
    Sagamihara-shi, Kanagawa 252-0375, Japan
  • Investigational Site Number : 39202
    Suita-shi, Osaka 565-0871, Japan
  • Investigational Site Number : 39201
    Iruma-gun, Saitama 350-0495, Japan
  • Investigational Site Number : 39208
    Bunkyo-ku, Tokyo 113-8655, Japan
  • Investigational Site Number : 39210
    Meguro-ku, Tokyo 152-8902, Japan
  • Investigational Site Number : 39204
    Setagaya City, Tokyo 157-0074, Japan
  • Investigational Site Number : 39209
    Sumida-ku, Tokyo 130-8575, Japan
  • Investigational Site Number : 39212
    Chiba, 60-0852, Japan
  • Investigational Site Number : 39203
    Hiroshima, 730-8619, Japan
  • Investigational Site Number : 39206
    Saitama-shi, 330-8777, Japan
  • Investigational Site Number : 48401
    Monterrey, Nuevo León 64460, Mexico
  • Investigational Site Number : 48402
    Chihuahua City, 31200, Mexico
  • Investigational Site Number : 48405
    Delegacion Benito Juarez, 03720, Mexico

Showing the first 100 of 155 sites across 26 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Kuter DJ, Ghanima W, Cooper N, Liebman HA, Zhang L, Hu Y, Miyakawa Y, Hutter-Kronke ML, Pascual-Izquierdo C, Lucchini E, Audia S, Cordoba M, Krenz H, Yao M, Daak A. Clinical activity and safety of rilzabrutinib in patients with previously treated immune thrombocytopenia (LUNA3): results from the open-label period of a phase 3 trial. Lancet Haematol. 2026 Sep 17:S2352-3026(26)00193-6. doi: 10.1016/S2352-3026(26)00193-6. Online ahead of print. PubMed 42753771 ↗
  • Kuter DJ, Ghanima W, Cooper N, Liebman HA, Zhang L, Hu Y, Miyakawa Y, Homenda W, Galindo LEM, Basquiera AL, Tan CW, Saydam G, Hutter-Kronke ML, Chai-Adisaksopha C, Gomez-Almaguer D, Tran H, Shin HJ, Dantas da Cunha Junior A, Lazar Z, Izquierdo CP, Kirgner I, Lucchini E, Kuzmina G, Fillitz M, Audia S, Taparia M, Cordoba M, Diab R, Yao M, Gouia I, Lee M, Daak A. Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study. Blood. 2025 Jun 12;145(24):2914-2926. doi: 10.1182/blood.2024027336. PubMed 40090011 ↗
  • Lin J, Radhakrishnan J. What Are Baskets, Umbrellas, and Platforms Doing in Nephrology Clinical Trials? J Am Soc Nephrol. 2025 Feb 3;36(8):1652-1654. doi: 10.1681/ASN.0000000648. No abstract available. PubMed 39899371 ↗
  • Kuter DJ, Bussel JB, Ghanima W, Cooper N, Gernsheimer T, Lambert MP, Liebman HA, Tarantino MD, Lee M, Guo H, Daak A. Rilzabrutinib versus placebo in adults and adolescents with persistent or chronic immune thrombocytopenia: LUNA 3 phase III study. Ther Adv Hematol. 2023 Oct 18;14:20406207231205431. doi: 10.1177/20406207231205431. eCollection 2023. PubMed 37869360 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in Jan 2025, 49 months.

Results were first posted in Feb 2026, 1 year 1 month after primary completion.

Of 41 industry-sponsored phase 3 interventional studies under Purpura, Thrombocytopenic, Idiopathic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 44. This study's 49 months is above that.

Counting every sponsor, half of 57 studies reached it within 28 months; a quarter within 22 and three quarters within 49.

Completion moved once since we started tracking on Sep 25, 2026: Aug 2026 → Sep 2026, on Oct 7, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2020
First posted
Sep 24, 2020
StartActual
Dec 14, 2020
Primary completionActual
Jan 15, 2025
CompletionActual
Sep 2, 2026was Aug 2026
Results first posted
Feb 23, 2026
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 7, 2026
Study completion
Aug 26, 2026→Sep 2, 2026 (actual)
Oct 7, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42753771 ↗
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Active, not recruiting→Completed
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42753771 ↗
    Study completion Aug 26, 2026→Sep 2, 2026 (now actual)
    + 3 other changes: identifiers, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04562766
Responsible party
Sponsor
First posted
Sep 24, 2020
Start date
Dec 14, 2020
Primary completion
Jan 15, 2025
Completion
Sep 2, 2026
Results posted
Feb 23, 2026
Last update
Oct 7, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rilzabrutinib

Start the discussion